-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$101.7054.35% Upside
Recent Analyst Forecasts and Stock Ratings
BioMarin Pharmaceutical Inc. Frequently Asked Questions
-
What analysts cover BioMarin Pharmaceutical Inc.?
BioMarin Pharmaceutical Inc. has been rated by research analysts at Cantor Fitzgerald, Robert W. Baird, Citigroup, Raymond James, Barclays, Scotiabank in the past 90 days.